Skip to main content
Top
Published in: Drugs & Aging 12/2015

01-12-2015 | Original Research Article

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects

Authors: Sybil Skinner-Robertson, Caroline Fradette, Sylvie Bouchard, Mohamad-Samer Mouksassi, France Varin

Published in: Drugs & Aging | Issue 12/2015

Login to get access

Abstract

Background

Tramadol is frequently used in geriatric patients; however, pharmacokinetic (PK) publications on tramadol and O-desmethyltramadol (ODM) in elderly patients are rare.

Objective

Our objective was to characterize the PK of tramadol and ODM, including absorption processes and covariates for tramadol, in elderly and young subjects after single-dose administration of 200-mg extended-release tablets.

Methods

We conducted a PK study in 15 elderly (aged ≥75 years) subjects with mild renal insufficiency and 20 young (18–40 years) subjects; blood and urine samples were collected for 48 h post-dose. Non-compartmental analysis (NCA) of each tramadol and ODM enantiomer included area under the concentration–time curve (AUC), terminal elimination rate (k el), total body clearance, volume of distribution (V area/ F), and renal clearance (Clr0–48). A one-compartment population model of total tramadol concentration was parameterized with clearance (CL/F), volume of distribution (V/F), and mixed order absorption (first-order and zero-order absorption rate constants with lag times).

Results

NCA demonstrated comparable maximum plasma concentration (C max) and AUC between age groups for tramadol enantiomers, but significant differences in V area/ F (mean 34 % higher) and k el (mean 28 % lower) in the elderly. PK of ODM were significantly different in the elderly for AUC0–inf (mean 35 % higher), Clr0–48 (mean 29 % lower), and k el (mean 33 % lower). The population analysis identified age as a covariate of V/F (young 305 L; elderly 426 L), with a 50 % longer mean elimination half-life in the elderly. No differences in absorption processes were observed.

Conclusions

Tramadol exposure was similar between the age groups; exposure to ODM was higher in elderly subjects.
Literature
1.
go back to reference Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.CrossRefPubMed Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.CrossRefPubMed
2.
go back to reference Jy C. Geriatric clinical pharmacology and clinical trials in the elderly. Transl Clin Pharmacol. 2014;22(2):64–9.CrossRef Jy C. Geriatric clinical pharmacology and clinical trials in the elderly. Transl Clin Pharmacol. 2014;22(2):64–9.CrossRef
3.
go back to reference Chien JY, Ho RJ. Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci. 2011;100(1):53–8.CrossRefPubMed Chien JY, Ho RJ. Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci. 2011;100(1):53–8.CrossRefPubMed
4.
go back to reference WHO. Better palliative care for older people. Coppenhagen: WHO Regional Office for Europe; 2004. WHO. Better palliative care for older people. Coppenhagen: WHO Regional Office for Europe; 2004.
5.
go back to reference Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46(2):313–40.CrossRefPubMed Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46(2):313–40.CrossRefPubMed
6.
go back to reference Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.CrossRefPubMed Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.CrossRefPubMed
7.
go back to reference Pascual ML, Fleming RR, Gana TJ, Vorsanger GJ. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Curr Med Res Opin. 2007;23(10):2531–42.CrossRefPubMed Pascual ML, Fleming RR, Gana TJ, Vorsanger GJ. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Curr Med Res Opin. 2007;23(10):2531–42.CrossRefPubMed
8.
go back to reference Fishman RL, Kistler CJ, Ellerbusch MT, Aparicio RT, Swami SS, Shirley ME, et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag. 2007;3(5):273–80.PubMed Fishman RL, Kistler CJ, Ellerbusch MT, Aparicio RT, Swami SS, Shirley ME, et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag. 2007;3(5):273–80.PubMed
9.
go back to reference Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag. 2008;4(2):87–97.PubMed Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag. 2008;4(2):87–97.PubMed
10.
go back to reference Beaulieu AD, Peloso P, Bensen W, Clark AJ, Watson CP, Gardner-Nix J, et al. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. Clin Ther. 2007;29(1):49–60.CrossRefPubMed Beaulieu AD, Peloso P, Bensen W, Clark AJ, Watson CP, Gardner-Nix J, et al. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. Clin Ther. 2007;29(1):49–60.CrossRefPubMed
11.
go back to reference Ummandi S SB, Raghavendra Rao NG, Srikanth Reddy M, Sanjeev Nayak B. Overview on controlled release dosage form. Int J Pharm Sci. 2013;3(4):258–69. Ummandi S SB, Raghavendra Rao NG, Srikanth Reddy M, Sanjeev Nayak B. Overview on controlled release dosage form. Int J Pharm Sci. 2013;3(4):258–69.
12.
go back to reference Mongin G. Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother. 2007;7(12):1775–84.CrossRefPubMed Mongin G. Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother. 2007;7(12):1775–84.CrossRefPubMed
13.
go back to reference Frink MC HH, Englberger W et al. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittel-Forschung. 1996;46(11):1029–36. Frink MC HH, Englberger W et al. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittel-Forschung. 1996;46(11):1029–36.
14.
go back to reference Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988;38(7):877–80.PubMed Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988;38(7):877–80.PubMed
15.
go back to reference Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997;53(3–4):235–9.CrossRefPubMed Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997;53(3–4):235–9.CrossRefPubMed
16.
go back to reference Garcia Quetglas E, Azanza JR, Cardenas E, Sadaba B, Campanero MA. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol. Biopharm Drug Dispos. 2007;28(1):19–33. Garcia Quetglas E, Azanza JR, Cardenas E, Sadaba B, Campanero MA. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol. Biopharm Drug Dispos. 2007;28(1):19–33.
17.
go back to reference Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009;10(7):1157–67.CrossRefPubMed Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009;10(7):1157–67.CrossRefPubMed
18.
go back to reference Lintz W, Erlacin S, Frankus E, Uragg H. Biotransformation of tramadol in man and animal (author’s transl). Arzneimittelforschung. 1981;31(11):1932–43.PubMed Lintz W, Erlacin S, Frankus E, Uragg H. Biotransformation of tramadol in man and animal (author’s transl). Arzneimittelforschung. 1981;31(11):1932–43.PubMed
19.
go back to reference Sadean MR, Glass PS. Pharmacokinetics in the elderly. Best Pract Res. 2003;17(2):191–205.CrossRef Sadean MR, Glass PS. Pharmacokinetics in the elderly. Best Pract Res. 2003;17(2):191–205.CrossRef
20.
21.
go back to reference Brouquet A, Cudennec T, Benoist S, Moulias S, Beauchet A, Penna C, et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg. 2010;251(4):759–65.CrossRefPubMed Brouquet A, Cudennec T, Benoist S, Moulias S, Beauchet A, Penna C, et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg. 2010;251(4):759–65.CrossRefPubMed
22.
go back to reference Karhu D, Groenewoud G, Potgieter MA, Mould DR. Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions. J Clin Pharmacol. 2010;50(12):1438–49.CrossRefPubMed Karhu D, Groenewoud G, Potgieter MA, Mould DR. Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions. J Clin Pharmacol. 2010;50(12):1438–49.CrossRefPubMed
23.
go back to reference Hernandez-Lopez C, Martinez-Farnos L, Karhu D, Perez-Campos T, Rovira S, Encina G. Comparative bioavailability between two tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol. 2006;28(6):373–8.CrossRefPubMed Hernandez-Lopez C, Martinez-Farnos L, Karhu D, Perez-Campos T, Rovira S, Encina G. Comparative bioavailability between two tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol. 2006;28(6):373–8.CrossRefPubMed
24.
go back to reference Karhu D, El-Jammal A, Dupain T, Gaulin D, Bouchard S. Pharmacokinetics and dose proportionality of three tramadol contramid OAD tablet strengths. Biopharm Drug Dispos. 2007;28(6):323–30.CrossRefPubMed Karhu D, El-Jammal A, Dupain T, Gaulin D, Bouchard S. Pharmacokinetics and dose proportionality of three tramadol contramid OAD tablet strengths. Biopharm Drug Dispos. 2007;28(6):323–30.CrossRefPubMed
25.
go back to reference Karhu D, Fradette C, Potgieter MA, Ferreira MM, Terblanche J. Comparative pharmacokinetics of a once-daily tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration. J Clin Pharmacol. 2010;50(5):544–53.CrossRefPubMed Karhu D, Fradette C, Potgieter MA, Ferreira MM, Terblanche J. Comparative pharmacokinetics of a once-daily tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration. J Clin Pharmacol. 2010;50(5):544–53.CrossRefPubMed
26.
go back to reference Karhu DBS. Pharmacokinetic evaluation of a novel once-a-day tramadol hydrochloride formulation. Rockville: American College of Clinical Pharmacology Annual Meeting; 2005. Karhu DBS. Pharmacokinetic evaluation of a novel once-a-day tramadol hydrochloride formulation. Rockville: American College of Clinical Pharmacology Annual Meeting; 2005.
27.
go back to reference Research FDACfDE. Guidance for industry: Bioanalytical method validation. Maryland: FDA; 2001. Research FDACfDE. Guidance for industry: Bioanalytical method validation. Maryland: FDA; 2001.
28.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.
29.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.PubMedCentralCrossRefPubMed Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.PubMedCentralCrossRefPubMed
30.
go back to reference Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer; 2006. p. 387 (xii). Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer; 2006. p. 387 (xii).
31.
go back to reference Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.PubMedCentralCrossRefPubMed Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.PubMedCentralCrossRefPubMed
33.
go back to reference Murthy BP, Skee DM, Danyluk AP, Brett V, Vorsanger GJ, Moskovitz BL. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol. Curr Med Res Opin. 2007;23(2):275–84.CrossRefPubMed Murthy BP, Skee DM, Danyluk AP, Brett V, Vorsanger GJ, Moskovitz BL. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol. Curr Med Res Opin. 2007;23(2):275–84.CrossRefPubMed
34.
go back to reference Grenier JLJ, Karhu D, editors. Tramadol: from immediate to extended release formulation. In: American College of Clinical Pharmacology 38th Annual Meeting: San Antonio; 12–15 Sept 2009. Grenier JLJ, Karhu D, editors. Tramadol: from immediate to extended release formulation. In: American College of Clinical Pharmacology 38th Annual Meeting: San Antonio; 12–15 Sept 2009.
35.
36.
go back to reference Likar R, Wittels M, Molnar M, Kager I, Ziervogel G, Sittl R. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther. 2006;28(12):2022–39.CrossRefPubMed Likar R, Wittels M, Molnar M, Kager I, Ziervogel G, Sittl R. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther. 2006;28(12):2022–39.CrossRefPubMed
37.
go back to reference Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung. 1986;36(8):1278–83.PubMed Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung. 1986;36(8):1278–83.PubMed
38.
go back to reference Kanaan M, Daali Y, Dayer P, Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin Pharmacol Toxicol. 2009;105(3):199–206.PubMedCentralCrossRefPubMed Kanaan M, Daali Y, Dayer P, Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin Pharmacol Toxicol. 2009;105(3):199–206.PubMedCentralCrossRefPubMed
39.
go back to reference Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011;90(1):143–50.CrossRefPubMed Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011;90(1):143–50.CrossRefPubMed
40.
go back to reference Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227–40.CrossRefPubMed Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227–40.CrossRefPubMed
41.
go back to reference Garrido MJ, Habre W, Rombout F, Troconiz IF. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res. 2006;23(9):2014–23.CrossRefPubMed Garrido MJ, Habre W, Rombout F, Troconiz IF. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res. 2006;23(9):2014–23.CrossRefPubMed
42.
go back to reference Imasogie NN, Singh S, Watson JT, Hurley D, Morley-Forster P. Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study. Pain Res Manag. 2009;14(2):103–8.PubMedCentralPubMed Imasogie NN, Singh S, Watson JT, Hurley D, Morley-Forster P. Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study. Pain Res Manag. 2009;14(2):103–8.PubMedCentralPubMed
43.
go back to reference Valle M, Garrido MJ, Pavon JM, Calvo R, Troconiz IF. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol in rats. J Pharmacol Exp Ther. 2000;293(2):646–53.PubMed Valle M, Garrido MJ, Pavon JM, Calvo R, Troconiz IF. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol in rats. J Pharmacol Exp Ther. 2000;293(2):646–53.PubMed
Metadata
Title
Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects
Authors
Sybil Skinner-Robertson
Caroline Fradette
Sylvie Bouchard
Mohamad-Samer Mouksassi
France Varin
Publication date
01-12-2015
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 12/2015
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0315-4

Other articles of this Issue 12/2015

Drugs & Aging 12/2015 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.